PET-guided omission of radiotherapy in Hodgkin lymphoma

Motoharu Shibusawa¹, Keisuke Kidoguchi², Jinichi Mori³, Tetsuya Tanimoto⁴

Affiliations

¹ IMS group Shinmatsudo Central General Hospital, Department of Hematology, Chiba, 270-0034, Japan. Electronic address: m_sibusawa@hotmail.com.
² Saga Central Hospital, Saga, Japan.
³ Jyoban Hospital of Tokiwa Foundation, Fukushima, Japan.
⁴ Navitas Clinic Kawasaki, Kanagawa, Japan.

PMID: 33932378
DOI: 10.1016/S1470-2045(21)00146-7

Comment

PET-guided omission of radiotherapy in Hodgkin lymphoma

Motoharu Shibusawa et al. Lancet Oncol. 2021 May.

. 2021 May;22(5):e181.

doi: 10.1016/S1470-2045(21)00146-7.

Authors

Motoharu Shibusawa¹, Keisuke Kidoguchi², Jinichi Mori³, Tetsuya Tanimoto⁴

Affiliations

¹ IMS group Shinmatsudo Central General Hospital, Department of Hematology, Chiba, 270-0034, Japan. Electronic address: m_sibusawa@hotmail.com.
² Saga Central Hospital, Saga, Japan.
³ Jyoban Hospital of Tokiwa Foundation, Fukushima, Japan.
⁴ Navitas Clinic Kawasaki, Kanagawa, Japan.

PMID: 33932378
DOI: 10.1016/S1470-2045(21)00146-7

No abstract available

PubMed Disclaimer

Conflict of interest statement

TT reports personal fees from Medical Network Systems, and Bionics, outside of the submitted work. All other authors declare no competing interests.

Comment in

PET-guided omission of radiotherapy in Hodgkin lymphoma - Authors' reply.
Borchmann P, Plütschow A, Görgen H. Borchmann P, et al. Lancet Oncol. 2021 May;22(5):e182. doi: 10.1016/S1470-2045(21)00210-2. Lancet Oncol. 2021. PMID: 33932379 No abstract available.

Comment on

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Borchmann P, Plütschow A, Kobe C, Greil R, Meissner J, Topp MS, Ostermann H, Dierlamm J, Mohm J, Thiemer J, Sökler M, Kerkhoff A, Ahlborn M, Halbsguth TV, Martin S, Keller U, Balabanov S, Pabst T, Vogelhuber M, Hüttmann A, Wilhelm M, Zijlstra JM, Moccia A, Kuhnert G, Bröckelmann PJ, von Tresckow B, Fuchs M, Klimm B, Rosenwald A, Eich H, Baues C, Marnitz S, Hallek M, Diehl V, Dietlein M, Engert A. Borchmann P, et al. Lancet Oncol. 2021 Feb;22(2):223-234. doi: 10.1016/S1470-2045(20)30601-X. Lancet Oncol. 2021. PMID: 33539742 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

PET-guided omission of radiotherapy in Hodgkin lymphoma

Affiliations

PET-guided omission of radiotherapy in Hodgkin lymphoma

Authors

Affiliations

Conflict of interest statement

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical